It will be of great interest to investigate the combinatorial effect of M-COPA and existing chemotherapeutic agents such as paclitaxel and cisplatin on these EGFR-mutated NSCLC cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.